Key Information Document

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

J. Lamarck Pharma (the "Sub-Fund")

a sub-fund of **SELECTRA INVESTMENTS SICAV (the "Fund")**

Class B – LU1224032463

PRIIP manufacturer: TMF Fund Management S.A.

legal.fundmanagement@tmf-group.com

For more information, call +352 42 71 71 1

The Commission de Surveillance du Secteur Financier (CSSF) in Luxembourg is responsible for supervising TMF Fund Management S.A. in relation to this Key Information Document.

J. Lamarck Pharma is authorised in Luxembourg and regulated by the CSSF.

This product is managed by TMF Fund Management S.A., which is authorised in Luxembourg and supervised by the CSSF.

Accurate as of: 24 August 2026

What is this product?

Type

- This product is a class of share of the Sub-Fund and denominated in EUR. The Fund SELECTRA INVESTMENTS SICAV is an open ended investment company with a variable capital and qualifies as an Undertaking for Collective Investment in Transferable Securities ("UCITS"), subject to Part I of the Luxembourg law of 17 December 2010 relating to undertakings for collective investment ("Investment Fund Law"), transposing Directive 2009/65/EC related to UCITS.
- As an investment fund, the return of the Sub-Fund depends on the performance of its underlying assets.

Objectives:

Investment objective:

- The main objective of this Sub-Fund is to profit from increasing share prices in the pharmaceutical sector worldwide. The focus is on mature top tier pharmaceutical companies and companies with interesting pipeline of products in development in a single or numerous markets. The followed investment policy will enable the Sub-Fund to increase overall return by active stock selection of companies, offering the most promising technology platform.

Investment policy:

- The Sub-Fund will take long positions in these shares issued mainly by worldwide issuers. In order to lower overall risk the Sub-Fund will NOT invest in derivatives (such as single stock futures, index futures, warrants or options) to meet the Sub-Fund's investment objective. The Sub-Fund may use financial derivative instruments for the purpose of hedging currency risks only.
- The Sub-Fund may invest up to 10% of its total net assets in shares/ units of UCITS and/or other UCIs (including ETF).
- Where the Sub-Fund invests in a UCITS and/or other UCIs linked to Kabuto S.A. (the "Investment Manager") of the Sub-Fund, the manager of the underlying UCITS respectively UCIs cannot charge subscription or redemption fees on account of the investment.
- The Sub-Fund is actively managed with no reference to a benchmark.
- The investments underlying this financial product do not take into account the EU criteria for environmentally sustainable economic activities.
- Given the objectives and risk and reward profile of the product, the recommended holding period is 5 years.

Redemption and Dealing: Redemption requests must be received by the Fund no later than 5 p.m (Luxembourg time) on the preceding business day.

Distribution Policy: This product does not pay dividends. Income generated by the Sub-Fund is reinvested and included in the value of your share.

Intended investor

This share-class is open to all type of investors who seek to invest worldwide in shares of companies active in the pharmaceutical sector.

The minimum investment is EUR 5.000.

Term

This product was incorporated for an undefined period. It may be terminated by the board of directors unilaterally under the conditions set forth in the prospectus of the Fund or by a decision of the general meeting of shareholders.


Practical information

Depositary: Quintet Private Bank (Europe) S.A., 43 Boulevard Royal, L-2449 Luxembourg.

Further information: The prospectus of the Fund and periodic reports are prepared for the entire Fund. Assets and liabilities of each sub-fund are segregated by law, meaning that the liabilities allocated to one sub-fund may not impact the other sub-fund. Shareholders are entitled to convert their shares in shares of another sub-fund/class of the fund, as more described in the prospectus. Copies of the prospectus and of the last annual and semi-annual reports of the entire Fund as well as other practical information such as the latest price for the shares may be obtained free of charge, in English, at the registered office of the Fund: 2, rue d'Alsace L-1122 Luxembourg Grand Duchy of Luxembourg.

What are the risks and what could I get in return?

Risks



The risk indicator assumes you keep the product for 5 years.

The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 4 out of 7, which is a medium risk class.

This rates the potential losses from future performance at a medium level, and poor market conditions could impact the capacity of TMF Fund Management S.A. to pay you.

Not all risks affecting the Sub-Fund are adequately captured by the summary risk indicator.

This rating does not take into account other risk factors which should be considered before investing, including pharmaceutical sector risk, equity risk, foreign currency risk, growth stocks risk, liquidity risk, market risk, small and mid-sized companies risk.

If TMF Fund Management S.A. is not able to pay you what is owed, you could lose your entire investment.

This product does not include any protection from future market performance so you could lose some or all of your investment.

Beside the risks included in the risk indicator, other risks may affect the Fund performance. Please refer to the prospectus, available free of charge at the registered office of the Fund.

Performance scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product over the last 10 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances.

Unfavourable: this type of scenario occurred for an investment between 30 August 2024 and 30 June 2026.

Moderate: this type of scenario occurred for an investment between 31 January 2017 and 31 January 2022.

Favourable: this type of scenario occurred for an investment between 31 May 2019 and 31 May 2024.

Recommended holding period		**5 years**	
Example Investment		**€ 10,000**	
Scenarios		**if you exit after 1 year**	**if you exit after 5 years** (recommended holding period)
Minimum	**There is no minimum guaranteed return. You could lose some or all of your investment.**		
Stress	**What you might get back after costs** Average return each year	**€ 5,105** -48.9%	**€ 4,284** -15.6%
Unfavourable	**What you might get back after costs** Average return each year	**€ 7,968** -20.3%	**€ 9,796** -0.4%
Moderate	**What you might get back after costs** Average return each year	**€ 9,865** -1.4%	**€ 12,627** 4.8%
Favourable	**What you might get back after costs** Average return each year	**€ 12,549** 25.5%	**€ 14,066** 7.1%

What happens if TMF Fund Management S.A. is unable to pay out?

You are exposed to the risk that the Fund might be unable to meet its obligations in connection with this product. This may materially adversely affect the value of the product and could lead to you losing some or all your investment in this product. A potential loss is not covered by an investor compensation or protection scheme.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

They are based on the following regulatory assumptions: (i) in the first year, you would get back the amount that you invested (0% annual return) and, for the other holding periods, the product performs as shown in the moderate scenario and (ii) 10,000 is invested.

Example Investment € 10,000	**if you exit after 1 year**	**if you exit after 5 years** (recommended holding period)
Total Costs	**€ 852**	**€ 3,877**
Annual cost impact*	**8.5%**	**5.8%**

(*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 10.5% before costs and 4.8% after costs.

Composition of costs

One-off costs upon entry or exit		**Annual cost impact if you exit after 1 year**
Entry costs	**3.00%** maximum of the amount you pay in when entering this investment. In case of conversion into shares of another class or another sub-fund, a maximum 1% conversion fee may be charged in favour of the Sub-Fund.	**€ 300**
Exit costs	**1.00%** of your investment before it is paid out to you.	**€ 100**
Ongoing costs taken each year		**Annual cost impact if you exit after 1 year**
Management fees and other administrative or operating costs	**4.10%** of the value of your investment per year. This is an estimate based on actual costs over the last year.	**€ 410**
Transaction costs	**0.14%** of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	**€ 14**
Incidental costs taken under specific conditions		**Annual cost impact if you exit after 1 year**
Performance fees	**0.28%** of the value of your investment per year. This is an estimate, calculated on an annualised basis, based on the average over the previous 5 years. We charge 10% of the positive performance over the high water mark. The actual amount will vary depending on how well your investment performs.	**€ 28**

How long should I hold it and can I take money out early?

Recommended holding period: 5 years

The RHP has been defined by taking into account the above investment policy and risk and reward profile. You should be prepared to stay invested for at least 5 years. However, you can redeem your investment without penalty prior to the end of the RHP or hold the investment longer. Redemption and conversion requests must be received by the Fund no later than 5 p.m. Luxembourg time on the applicable valuation day. Any cashing-in before the end of the RHP may have a negative consequence on your investment.

How can I complain?

If you have any complaint about this product, please find the steps to be followed for lodging any complaint at legal.fundmanagement@tmf-group.com. You can also send your complaint to the Fund's management company at: TMF FUND MANAGEMENT S.A. (Complaints Officer) 46A, Avenue John F. Kennedy, L-1855 Luxembourg, or by e-mail to complaint.fundmanagement@tmf-group.com. If you have a complaint about the person that advised you about this product, or who sold it to you, they will tell you where to complain.

Other relevant information

Investment Manager: J. Lamarck Asset Management S.A. 3, Via Greina B6900 Lugano Switzerland.

Performance scenarios You can find previous performance scenarios updated on a monthly basis at https://tmffm.priips-scenarios.com/LU1224032463/en/KID/.

Past performance You can download the past performance over the last 10 years from our website at https://tmffm.priips-performance-chart.com/LU1224032463/en/KID/.

Supplementary information for investors in Switzerland: The state of origin of the Fund is Luxembourg. The Swiss representative is ACOLIN Fund Services AG, Maintower, Thurgauerstrasse 36/38, CH-8050 Zurich, and the Swiss paying agent is Cornèr Banca SA, Via Canova 16, CH-6900 Lugano. The prospectus, the key information documents, the articles of incorporation, as well as the annual and semi-annual reports may be obtained free of charge from the representative.